Research Topics
Species | William G WoodsSummaryAffiliation: Children's Healthcare of Atlanta Country: USA Publications
| Collaborators
|
Detail Information
Publications
Screening of infants and mortality due to neuroblastomaWilliam G Woods
AFLAC Cancer Center, Emory University and Children s Healthcare of Atlanta, GA 30322, USA
N Engl J Med 346:1041-6. 2002..However, it is unknown whether routine screening for neuroblastoma reduces mortality due to this disease...- Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer GroupWilliam G Woods
AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
J Clin Oncol 20:434-40. 2002..We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children's Cancer Group protocol 2891... - Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleepWilliam G Woods
Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta Emory University Department of Pediatrics, Atlanta, Georgia 30322, USA
Pediatr Blood Cancer 46:565-9. 2006..This brief review looks at both the advances over the last three decades as well as discusses the challenges moving forward for ultimately curing all children with this disease... - "Let's try it one more, once"William G Woods
Department of Pediatric Hematology/Oncology, Hematopoietic Transplantation, Children's Healthcare of Atlanta, Atlanta, Georgia, USA
Pediatr Blood Cancer 46:271-2. 2006 - Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survivalSteven Neudorf
American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
Blood 103:3655-61. 2004..014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS... - Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectivelyLubing Gu
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA
J Biol Chem 279:52141-9. 2004..Furthermore, loss of p53-mediated control over ETS-1-dependent transactivation of IKKalpha may represent a novel pathway for the constitutive activation of NF-kB-mediated gene expression and therapy resistance in cancer... 
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology GroupJohn T Horan
Aflac Cancer Center and Blood Disorder Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30332, USA
J Clin Oncol 26:5797-801. 2008..Others have maintained that transplantation in first remission should be reserved for patients with high-risk disease. We performed this study to determine how disease risk influences the efficacy of BMT...- Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53Muxiang Zhou
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
Oncogene 22:8137-44. 2003..Our data suggest that IkBm simultaneously downregulates NF-kB activation and sequesters p53 in the cytoplasm, thus enhancing NF-kB-regulated apoptosis but blocking p53-dependent apoptosis... - Screening for neuroblastoma: the final chaptersWilliam G Woods
Children's Healthcare of Atlanta at Emory, Atlanta, GA, USA
J Pediatr Hematol Oncol 25:3-4. 2003 
Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology GroupLillian Sung
Department of Paediatrics and Program in Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, ON, Canada
J Pediatr Hematol Oncol 34:e30-5. 2012..Intensive timing was associated with more severe infections compared with standard timing induction. Prophylactic strategies are likely more important with intensive induction regimens...- Intracavitary cisplatin therapy for pediatric malignanciesHoward M Katzenstein
AFLAC Cancer Center and Blood Disorders Services, Division of Pediatric Hematology Oncology, Emory University School of Medicine and Children s Healthcare of Atlanta, Atlanta, Georgia, USA
Pediatr Blood Cancer 55:452-6. 2010..The aim of the study was to determine the toxicity and efficacy of locally instilled intracavitary cisplatin in patients with recurrent tumors in closed body cavities... - PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cellsMuxiang Zhou
Division of Pediatric Hematology Oncology Bone Marrow Transplantation, Emory University School of Medicine, 2040 Ridgewood Drive N E, Atlanta, GA 30322, USA
Cancer Res 63:6357-62. 2003..Furthermore, loss of PTEN can result in resistance to apoptosis by activating MDM2-mediated antiapoptotic mechanism... - The American Society of Pediatric Hematology/Oncology Distinguished Career Award goes to William KrivitWilliam G Woods
Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Emory University School of Medicine, Atlanta, Georgia, USA
J Pediatr Hematol Oncol 25:279-81. 2003 - Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemiaWilliam Tse
Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, USA
Blood 104:3058-63. 2004..01). AF1q expression may correlate with clinical outcome in pediatric AML, although it is not clear if AF1q is simply a marker of a more primitive phenotype or contributes directly to leukemogenesis... - Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentationDorothy R Barnard
Dalhousie University, Halifax, NS
Blood 100:427-34. 2002..The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standard-timing induction appears less effective for this population... - Screening for neuroblastoma: a resurrected idea?John M Maris
Center for Childhood Cancer Research, Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
Lancet 371:1142-3. 2008 - Incidence of neuroblastoma after a screening programStephane Barrette
Hopital Ste Justine, Montréal Centre Hospitalier de l Université Laval, Ste Foy, Quebec, Canada
J Clin Oncol 25:4929-32. 2007..We examined the postscreening incidence of neuroblastoma in the subsequent 5-year birth cohort (May 1994 to April 1999), with follow-up to 2002, to determine whether the incidence remained increased... - Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213Sharon M Castellino
ETSU Quillen College of Medicine, Johnson City, Tennessee, USA
Pediatr Blood Cancer 50:9-16. 2008..The majority of childhood acute myeloid leukemia (AML) patients lack a matched-related bone marrow transplant (BMT) donor in first remission... - Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology GroupDorothy R Barnard
IWK Health Centre, Halifax, Nova Scotia, Canada
Pediatr Blood Cancer 49:17-22. 2007..Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features... - Treatment complications in children diagnosed with neuroblastoma during a screening programStephane Barrette
Hopital Ste Justine, Montreal, Quebec, Canada
J Clin Oncol 24:1542-5. 2006..We assess treatment complications in the patients diagnosed during this screening program... - Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology GroupRichard Aplenc
Pediatric Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Blood 108:74-80. 2006..Fewer black children than expected had an available family marrow donor... - Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American viewAllen R Chen
Department of Oncology, Division of Pediatric Oncology, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287, USA
Br J Haematol 118:378-84. 2002 - Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemiaEric L Sievers
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA the Department of Pediatrics, University of Washington, Seattle, WA 98109, USA
Blood 101:3398-406. 2003..Among patients in whom a marrow sample was available for analysis at the end of consolidation therapy, overall survival at 3 years was 41% versus 69% for patients with and without occult leukemia, respectively (P =.0058)... - All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman
Northwestern University, Feinburg School of Medicine, Department of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Blood 100:4298-302. 2002..The improvement in outcome with ATRA in APL was maintained with long-term follow-up... - Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screeningLee Soderstrom
Department of Economics, McGill University, 855 Sherbrooke W, Montreal, Quebec, H3A 2T7, Canada
J Natl Cancer Inst 97:1118-24. 2005..It screened most Quebec newborns between 1989 and 1994 for neuroblastoma. As previously reported, the screening did not reduce neuroblastoma mortality and caused adverse health effects... - Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer GroupTodd A Alonzo
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
J Pediatr Hematol Oncol 24:627-35. 2002.... - Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891Alan S Gamis
Section of Hematology Oncology Blood and Marrow Transplantation, Children s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
J Clin Oncol 21:3415-22. 2003..To determine the outcome of children with Down syndrome (DS) and acute myeloid leukemia (AML) receiving standard timing chemotherapy without bone marrow transplantation (BMT), with determination of prognostic factors... - Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemiaSoheil Meshinchi
Fred Hutchinson Cancer Research Center, Division of Clinical Research, D4 100, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109 1024, USA
Blood 102:1474-9. 2003..38). Activating mutations in the RTK/ras signaling pathway are common in pediatric AML, and their presence may identify a population at higher risk of poor outcome who may benefit from allogeneic BM transplantation... - Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemiaDonna L Johnston
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Br J Haematol 123:431-5. 2003..However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy... - Substitute "prostate cancer" for "neuroblastoma"?William G Woods
J Clin Oncol 20:1154-5. 2002 - Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective studyHenrik Hasle
Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Blood 109:4641-7. 2007..Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future risk-group stratification... - Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemiaDonna L Johnston
Division of Hematology Oncology, Children s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
J Clin Oncol 23:9172-8. 2005..CNS relapse of pediatric acute myeloid leukemia (AML) is an infrequent occurrence. This review examines the risk factors and therapy used for patients with an isolated CNS relapse... - Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961Draga Barbaric
Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
Blood 109:2314-21. 2007..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML... - Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology GroupJoanne M Hilden
The Children s Hospital at the Cleveland Clinic, OH 44195, USA
Blood 108:441-51. 2006..MLL/11q23 rearrangement, CD10 expression, and age are important prognostic factors in infant ALL, but molecular 11q23 translocation partners do not predict outcome... - Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer GroupKathryn E Dusenbery
University of Minnesota, Minneapolis, USA
J Pediatr Hematol Oncol 25:760-8. 2003..To describe features of patients with acute myeloid leukemia presenting with extramedullary leukemic tumors (EML)...